Everand Logo

Welcome to Everand!

  • STAT

    Precautions are in place. Now U.S. hospitals and states ready for more cases of novel virus from China

    U.S. hospitals and states are prepared for more cases of a novel virus from China — and looking out for some particular twists.
    by Shraddha Chakradhar and Andrew Joseph Jan 24, 2020 5 minutes
    A man in his 30s, who was the first U.S. case of a novel coronavirus spreading in China, was treated at Providence Regional Medical Center in Everett, Wash.

    It seemed like it was only a matter of time.

    Even before the first U.S. case of a novel coronavirus that’s broken out in China was confirmed Tuesday, American health officials and hospitals were braced to respond. Hospitals and clinics were adapting their screening protocols to ask about travel to Wuhan, the city where the spread has been centered. State health departments were relaying messages to local providers, alerting them to be on the lookout for the infection’s symptoms. Labs were set to collect patient samples and ship them off for diagnostic testing.

    Even though this is a new virus, health officials said this was the type of situation they anticipated. They’ve prepared before for other emerging infectious diseases, including Zika and Ebola, as well as other coronaviruses like SARS and MERS. For this current outbreak, federal health officials for surveillance, testing, and care of patients, and hospitals have been following

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks